- Home
- ZYME vs UWMC Comparison
ZYME vs UWMC Comparison
Compare ZYME & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- UWMC
- Stock Information
- Founded
- ZYME 2003
- UWMC 1986
- Country
- ZYME United States
- UWMC United States
- Employees
- ZYME N/A
- UWMC N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- ZYME Health Care
- UWMC Finance
- Exchange
- ZYME Nasdaq
- UWMC Nasdaq
- Market Cap
- ZYME 846.1M
- UWMC 872.1M
- IPO Year
- ZYME 2017
- UWMC N/A
- Fundamental
- Price
- ZYME $11.43
- UWMC $4.31
- Analyst Decision
- ZYME Buy
- UWMC Hold
- Analyst Count
- ZYME 7
- UWMC 8
- Target Price
- ZYME $19.50
- UWMC $6.86
- AVG Volume (30 Days)
- ZYME 449.0K
- UWMC 5.6M
- Earning Date
- ZYME 05-08-2025
- UWMC 05-06-2025
- Dividend Yield
- ZYME N/A
- UWMC 9.30%
- EPS Growth
- ZYME N/A
- UWMC N/A
- EPS
- ZYME N/A
- UWMC N/A
- Revenue
- ZYME $93,384,000.00
- UWMC $2,486,541,000.00
- Revenue This Year
- ZYME $34.23
- UWMC $7.37
- Revenue Next Year
- ZYME $68.78
- UWMC $22.42
- P/E Ratio
- ZYME N/A
- UWMC N/A
- Revenue Growth
- ZYME 85.05
- UWMC 10.39
- 52 Week Low
- ZYME $8.21
- UWMC $3.89
- 52 Week High
- ZYME $17.70
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- ZYME 45.92
- UWMC 47.87
- Support Level
- ZYME $11.46
- UWMC $3.89
- Resistance Level
- ZYME $11.81
- UWMC $4.25
- Average True Range (ATR)
- ZYME 0.59
- UWMC 0.18
- MACD
- ZYME -0.05
- UWMC 0.05
- Stochastic Oscillator
- ZYME 27.62
- UWMC 84.16
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.